Evidence map›Paper›PMID 18658277›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2008

Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition.

Weiguo Chen, Srikanth Pendyala, Viswanathan Natarajan, Joe G N Garcia, Jeffrey R Jacobson

Abstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Post-translational modifications of S1PR1 and endothelial barrier regulation.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2020
    Review
  14. Article
  15. Review
  16. Innovations in asthma therapy: is there a role for inhaled statins?Expert review of respiratory medicine · 2018
    Review
  17. Article
  18. Article
  19. Article
  20. Bacteria and endothelial cells: a toxic relationship.Current opinion in microbiology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Weiguo ChenSect. of Pulmonary and Critical Care Medicine, Pritzker School of Medicine, Univ. of Chicago, Chicago, IL 60637. jjacobso@medicine.bsd.uchicago.edu).
Srikanth Pendyala
Viswanathan Natarajan
Joe G N Garcia
Jeffrey R Jacobson

Funding

Tissue Culture Biomechanical CoreP01HL058064 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LANGAN, GEORGE PARSONS · 1998 to 2012
$27.8M
Endothelial Barrier Regulation by SimvastatinK08HL077134 · NHLBI · UNIVERSITY OF CHICAGO · PI JACOBSON, JEFFREY R · 2005 to 2009
$625k
NHLBI NIH HHS HL-58064NHLBI NIH HHS HL-71411NHLBI NIH HHS K08 HL077134
6 · The paper itself

Abstract

The statins, hydroxy-3-methylglutaryl-CoA reductase inhibitors that lower serum cholesterol, exhibit myriad clinical benefits, including enhanced vascular integrity. One potential mechanism underlying increased endothelial cell (EC) barrier function is inhibition of geranylgeranylation, a covalent modification enabling translocation of the small GTPases Rho and Rac to the cell membrane. While RhoA inhibition attenuates actin stress fiber formation and promotes EC barrier function, Rac1 inhibition at the cell membrane potentially prevents activation of NADPH oxidase and subsequent generation of superoxides known to induce barrier disruption. We examined the relative regulatory effects of simvastatin on RhoA, Rac1, and NADPH oxidase activities in the context of human pulmonary artery EC barrier protection. Confluent EC treated with simvastatin demonstrated significantly decreased thrombin-induced FITC-dextran permeability, a reflection of vascular integrity, which was linked temporally to simvastatin-mediated actin cytoskeletal rearrangement. Compared with Rho inhibition alone (Y-27632), simvastatin afforded additional protection against thrombin-mediated barrier dysfunction and attenuated LPS-induced EC permeability and superoxide generation. Statin-mediated inhibition of both Rac translocation to the cell membrane and superoxide production were attenuated by geranylgeranyl pyrophosphate (GGPP), indicating that these effects are due to geranylgeranylation inhibition. Finally, thrombin-induced EC permeability was modestly attenuated by reduced Rac1 expression (small interfering RNA), whereas these effects were made more pronounced by simvastatin pretreatment. Together, these data suggest EC barrier protection by simvastatin is due to dual inhibitory effects on RhoA and Rac1 as well as the attenuation of superoxide generation by EC NADPH oxidase and contribute to the molecular mechanistic understanding of the modulation of EC barrier properties by simvastatin.

Indexed as

Capillary PermeabilityEndothelium, VascularGTPase-Activating ProteinsGTP PhosphohydrolasesHumansNADPH OxidasesPhosphoproteinsPulmonary Arteryrac1 GTP-Binding ProteinrhoA GTP-Binding ProteinRNA, Small InterferingSimvastatinSuperoxidesARHGAP31 protein, humanGTPase-Activating ProteinsGTP PhosphohydrolasesNADPH OxidasesPhosphoproteinsrac1 GTP-Binding ProteinRAC1 protein, humanrhoA GTP-Binding ProteinRNA, Small InterferingSimvastatinSuperoxides

Identifiers

PMID18658277
PMCPMC2575942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.